Athymic Animal and Preclinical Therapeutics Shared Resource

无胸腺动物和临床前治疗共享资源

基本信息

批准号：
9759052
负责人：
Analisa DiFeo
金额：
$ 0.93万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9759052
关键词：
AML/MDS Accounting Animal Model Animals Biomedical Research Breast Cancer Patient CRISPR/Cas technology Cancer Center Support Grant Clinic Collaborations Collection Complex Comprehensive Cancer Center Consent Consultations Data Development Developmental Therapeutics Program Doctor of Philosophy Drug Kinetics Drug resistance Endometrial Carcinoma Evolution Funding Future Genetic Genetic Models Genetic Transcription Genetically Engineered Mouse Hematologic Neoplasms Hematological Disease Histologic Human Immunodeficient Mouse Immunotherapy Individual Institutes Institutional Review Boards Investigational Drugs Laboratories Laboratory Personnel Malignant Neoplasms Malignant neoplasm of ovary Messenger RNA Methods Mission Modeling Molecular Medicine Multiple Myeloma Mus Mutation Patients Pharmacodynamics Pharmacology Point Mutation Principal Investigator Procedures Proteins Protocols documentation Research Research Personnel Research Project Grants Resource Sharing Ribonucleotide Reductase Inhibitor Services Site Somatic Mutation Source Technical Expertise Techniques Technology Transfer Testing Therapeutic Tissues Training Transgenic Organisms Translational Research Tumor Angiogenesis Tumor Bank Universities Xenograft Model Xenograft procedure biobank college cost drug development experimental study genetic evolution humanized mouse immunosuppressed member mouse model novel novel drug combination oncology pre-clinical preclinical evaluation preclinical study professor programs service utilization small molecule tumor tumor xenograft

项目摘要

ATHYMIC ANIMAL AND PRECLINICAL THERAPEUTICS SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Athymic Animal and Preclinical Therapeutics Shared Resource (Athymic SR) is an essential asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of scientific program involvement and reflected in the number of investigators who use this SR. Last year alone, 55 investigators, 80% of whom were Case CCC members, accounting for 86% of total usage, from 6 out of the Center’s 7 Programs used the SR. The mission of the Athymic SR is to provide support, technical expertise and services to Case CCC investigators using immunosuppressed mouse models in their research, in a depth and extent that could not be supported by individual laboratories. The Athymic SR includes two main sites: one at Case Western Reserve University (CWRU), housed in both the Biomedical Research and Wolstein Research Buildings, and one at Cleveland Clinic (CC) Taussig Cancer Institute (TCI). The Specific Aims of the Athymic SR are to: 1. Provide all Case CCC members the ability to purchase immunodeficient mice with no delay and at significantly reduced cost vs. those from commercial sources, and the ability to perform human xenograft tumor studies including patient-derived xenograft (PDX) models. 2. Provide professional consultation and guidance for selecting the most appropriate animal models to test new anti-tumor therapeutic compounds, and obtain pre-clinical pharmacokinetic / pharmacodynamic data for Investigational New Drug (IND)-enabling studies. 3. Provide services utilizing genetically-engineered mouse models (GEMM) that inform about the functional relevance of specific genetic deletions or mutations in tumor evolution or development of drug-resistance. 4. Train principal investigators’ laboratory personnel in experimental animal techniques and protocols to facilitate technology transfer to individual laboratories. At last review, the Athymic SR was rated Outstanding to Exceptional. Throughout the current funding cycle (2012-2016), the Athymic SR provided services to 106 registered users, 76 (72%) of whom are Case CCC members, representing 6 out of 7 Case CCC programs. Athymic SR services are provided to investigators in 4 different ways: 1) collaborative mode, in which investigators interact with the SR staff; 2) advanced training format, whereby users conduct their experiments in an independent mode; 3) full service approach, in which the SR staff perform entire experimental procedures; (4) interactive arrangement, in which SR staff provide guidance in developing patient-derived xenograft (PDX) models. All Case CCC members have formal access to this jointly managed SR.

无关动物和临床前治疗药物共享资源项目摘要/摘要无胸腺动物和临床前治疗药物共享资源（Anymic SR）是案例的重要资产综合癌症中心（CASE CCC）成员的研究，由科学计划的广度说明参与并反映在使用此SR的调查人员数量中。仅去年，有55名调查员，80％他们是CASE CCC成员，占总用法的86％，该中心的7个计划中有6个使用了SR。小心理SR的任务是为CASC提供支持，技术专长和服务研究人员在其研究中使用免疫抑制的小鼠模型的深度和程度不可能由个别实验室的支持。小心理SR包括两个主要站点：一个在Case Western Reserve上在生物医学研究和沃尔斯坦研究建筑中，大学（CWRU）以及克利夫兰诊所（CC）Taussig癌症研究所（TCI）。小心理SR的具体目的是： 1。提供所有案例CCC成员的能力，可以无延迟购买免疫缺陷小鼠与商业来源和执行人类异种移植的能力相比，成本显着降低了肿瘤研究，包括患者衍生的Xenographic（PDX）模型。 2。提供专业咨询和指导，以选择最合适的动物模型进行测试新的抗肿瘤治疗化合物，并获得临床前药代动力学 /药效学数据用于研究新药（IND）的增强研究。 3。提供利用一般设计的鼠标模型（GEMM）提供的服务，这些服务告知功能特定遗传缺失或突变在肿瘤进化或耐药性发展中的相关性。 4.培训实验动物技术和协议中的首席研究人员的实验室人员促进技术转移到个别实验室。在上次审查中，无性SR被评为出色。在当前的整个资金周期中（2012-2016），无性SR为106位注册用户提供服务，其中76名（72％）是CASE CCC 成员，代表7个案例CCC计划中的6个。 Anymic SR服务以4种不同的方式向调查人员提供：1）协作模式，其中调查人员与SR员工互动； 2）高级培训格式，用户在其中进行实验独立模式； 3）SR员工执行整个实验程序的全面服务方法；（4）交互式安排，在该安排中，SR员工为开发患者衍生的Xenographographic（PDX）提供了指导型号。所有案例CCC成员都可以正式访问该共同管理的SR。